Kolexia
Lenain Pascal Hématologie
Lenain Pascal
Hématologie
Centre Henri-Becquerel
Rouen, France
146 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Leucémies Leucémie myéloïde chronique BCR-ABL positive Lymphomes Tumeurs à plasmocytes Leucémie myéloïde Lymphome B diffus à grandes cellules Lymphome B Maladie de Hodgkin

Collaborateurs

Voir plus
Jardin Fabrice
Jardin Fabrice
Centre Henri-Becquerel, Rouen, France
Lepretre Stephane
Lepretre Stephane
Centre Henri-Becquerel, Rouen, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Sanofi
4 collaboration(s)
Dernière en 2023
Janssen
3 collaboration(s)
Dernière en 2023
Amgen
2 collaboration(s)
Dernière en 2020
MSD
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
EXCALIBER-RRMM: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Essai Clinique (Celgene)   12 mars 2024
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206
65th ASH Annual Meeting Abstracts   02 novembre 2023
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study.
Annals of hematology   26 octobre 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica   01 octobre 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock
Proceedings of Reanimation 2023, the French Intensive Care Society International Congress   14 juin 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica   01 mai 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock.
Clinical nutrition ESPEN   22 avril 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
British journal of haematology   27 mars 2023